

## Phase I Repeat Dose Canine Anti-cancer Monepantel Tablets Demonstrate High Performance

- New data on canine repeat dose monepantel and monepantel sulfone blood levels, providing for flexible treatment regimens
- Serum levels in healthy beagle dogs administered 1 tablet daily for 9 consecutive days exceed predicted anti-cancer activity target values
- Serum levels in healthy beagle dogs administered 5 tablets daily for 9 consecutive days are triple target values
- Results guide dosing strategies for upcoming anti-cancer Phase II trials

**6 May 2019 – Perth, Australia: PharmAust Ltd (ASX:PAA)**, a clinical-stage oncology company, is pleased to announce that it has received further positive results from its ongoing Phase I trial program in healthy beagle dogs. With this new data PharmAust is preparing trial design and commencement of its Phase II trial program in dogs with cancer

This latest trial tested safety and serum levels of monepantel and monepantel sulfone in the blood of healthy dogs administered either 1 or 5 tablets every day for 9 days. PharmAust has shown previously that both monepantel and its major metabolite, monepantel sulfone, provide anti-cancer activity. It is important to understand steady-state blood levels of both active molecules over long-term drug administration.

One tablet daily provides long-term blood levels that exceed PharmAust's target level, while five tablets daily tripled PharmAust's target levels. These observations give PharmAust much flexibility in designing dosing schedules for therapeutic treatment of dogs with cancer.

No changes in any clinical signs were reported at either dosing level by the US-based independent research organisation conducting the study, with monepantel being well tolerated.

PharmAust's Chief Scientific Officer Dr Richard Mollard stated, "Results from the Phase I tests continue to be very encouraging. With these new results PharmAust can assess several different clinical strategies to determine which best fits monepantel's anti-cancer properties. One treatment strategy may offer low-dose maintenance therapy to keep problematic cancers under control while a second strategy would investigate short-term very high dose therapy aimed at eradicating other cancers."

**Enquiries:**

**Dr Roger Aston**  
**Executive Chairman and CEO**  
**Tel: 0402 762 204**  
[rogeraston@pharmaust.com](mailto:rogeraston@pharmaust.com)

**Dr Richard Mollard**  
**Chief Scientific Officer**  
**Tel: 0418 367 855**  
[rmollard@pharmaust.com](mailto:rmollard@pharmaust.com)

**About PharmAust (PAA):**

PAA is a clinical-stage company developing targeted cancer therapeutics for humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. PAA's subsidiary, Epichem, is a successful contract medicinal chemistry company that generated \$3m revenues in FY2018.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs; was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug to Phase 2 clinical trials.

[www.pharmaust.com](http://www.pharmaust.com)